TP53 and ovarian carcinoma: A gain-of-function mutation of the p53 gene is characteristic of the most common subtype of EOC, high-grade serous ovarian cancer (169), therefore ovarian cancer patients with a high HIF-1 expression profile may benefit from therapies directly targeting HIF-1.